Allergan rejects Valeant's $48bn buyout offer
This article was originally published in Scrip
Executive Summary
Allergan is not going down without a fight, even if the battle includes aggressive maneuvers by Valeant Pharmaceuticals, whose unsolicited $48bn bid to buy the Southern California drug maker has now been rejected by Allergan's board of directors.